Hundreds of additional Stryker hip lawsuit plaintiffs will benefit from a settlement involving the company’s recalled Rejuvenate and AGB II Modular-Neck stems. According to a statement issued last month by Stryker Corp., the $1 billion settlement program has been extended to individuals who underwent revision of their Rejuvenate and/ or AGB II hip stem as of December 19, 2016 for a recall-related reason.

Stryker Hip Recall & Settlement

Stryker recalled the Rejuvenate and ABG II stems from the global market in 2012,after the company acknowledged that they were prone to fretting and corrosion at the modular-neck junction, an occurrence that can lead to premature device failure and other painful complications. Some 20,000 people were implanted with the components prior to their recall, and Stryker’s announcement prompted thousands of people to file lawsuits for injuries related to the issue. The Stryker hip settlement agreement was put in place two years ago, but only included Rejuvenate and ABG II patients who had undergone revision surgery as of November 3, 2014, as well as patients who required revision but were unable to undergo surgery for medical reasons.

The expanded settlement was announced on December 19, 2016, via an Order issued in the U.S. District Court, District of Minnesota, where thousands of Stryker hip lawsuits were centralized for the purposes of coordinated pretrial proceedings. The agreement also applies to thousands of additional cases pending in a multicounty litigation established in New Jersey’s Bergen County Superior Court. The Order directs Stryker hip attorneys to identify all clients with filed and unfiled cases that have not been previously registered and which remain unsettled. They have also been redirected to update the revision status for plaintiffs who were previously registered, but whose cases have not settled or resolved.

As was the case with the original agreement, plaintiffs eligible to participate in the expanded Stryker hip settlement will be eligible for a base award of $300,000 for each revised hip. Unrepresented claimants are eligible for 71 percent of the base award, or $213,000. Awards will be reduced for compounding medical factors, such as smoking.

Stryker said payments made under the agreement will likely begin in late 2017. While the settlement will end a large potion of the current litigation, some lawsuits will remain.

“The final outcome of this matter is dependent on many variables that are difficult to predict. The ultimate cost to entirely resolve this matter may be materially different than the amount of the current estimate,” the Stryker statement said.

Hip Replacement Attorneys

Bernstein Liebhard LLP represents the victims of defective hip implants. To discuss a case with our legal team, please call 877-779-1414 to arrange a free, no-obligation legal review.

Published January 9, 2017 by